- Community-Beiträge
- Aktuellste Threads
| Geld/Brief | 4,70 € / 4,88 € |
| Spread | +3,83% |
| Schluss Vortag | 4,86 € |
| Gehandelte Stücke | 0 |
| Tagesvolumen Vortag | - |
| Tagestief 4,74 € Tageshoch 4,80 € | |
| 52W-Tief 1,65 € 52W-Hoch 6,00 € | |
| Jahrestief 4,30 € Jahreshoch 5,45 € | |
| Umsatz in Mio. | - |
| Operatives Ergebnis (EBIT) in Mio. | -103,20 $ |
| Jahresüberschuss in Mio. | -95,88 $ |
| Umsatz je Aktie | - |
| Gewinn je Aktie | -0,48 $ |
| Gewinnrendite | -55,92% |
| Umsatzrendite | - |
| Return on Investment | -45,04% |
| Marktkapitalisierung in Mio. | 608,45 $ |
| KGV (Kurs/Gewinn) | -6,40 |
| KBV (Kurs/Buchwert) | 3,53 |
| KUV (Kurs/Umsatz) | - |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +80,54% |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 4,68 € | -3,31% | 4,84 € | 12:30 | |
| Frankfurt | 4,74 € | -1,66% | 4,82 € | 08:01 | |
| München | 4,84 € | 0 % | 4,84 € | 08:01 | |
| Stuttgart | 4,70 € | -2,49% | 4,82 € | 13:31 | |
| L&S RT | 4,79 € | -0,62% | 4,82 € | 13:53 | |
| NYSE | 5,63 $ | -4,90% | 5,92 $ | 04.03.26 | |
| Nasdaq | 5,615 $ | +0,09% | 5,61 $ | 04.03.26 | |
| AMEX | 5,67 $ | -3,08% | 5,85 $ | 04.03.26 | |
| Tradegate | 5,15 € | +6,85% | 4,82 € | 02.03.26 | |
| Quotrix | 4,84 € | +0,83% | 4,80 € | 07:27 | |
| Gettex | 4,80 € | -1,23% | 4,86 € | 13:43 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 04.03.26 | 4,80 | 0 |
| 03.03.26 | 4,82 | 0 |
| 02.03.26 | 5,15 | 967 |
| 27.02.26 | 5,05 | 0 |
| 26.02.26 | 5,05 | 0 |
| 25.02.26 | 4,96 | 14 |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 4,96 € | -3,23% |
| 1 Monat | 4,52 € | +6,19% |
| 6 Monate | 3,04 € | +57,89% |
| 1 Jahr | 2,26 € | +112,39% |
| 5 Jahre | - | - |
| Marktkapitalisierung | 1,11 Mrd. € |
| Aktienanzahl | 203,47 Mio. |
| Streubesitz | 11,72% |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +14,16% | NEA Management Company, LLC |
| +10,18% | Bain Capital Life Sciences Investors, LLC |
| +7,15% | TCG Crossover Management, LLC |
| +6,37% | Vestal Point Capital LP |
| +5,66% | BlackRock Inc |
| +5,14% | VR Adviser, LLC |
| +4,89% | Vanguard Group Inc |
| +4,82% | Nantahala Capital Management, LLC |
| +4,61% | Deerfield Management Co |
| +3,95% | Farallon Capital Management, L.L.C. |
| +2,08% | ADAR1 Capital Management LLC |
| +2,04% | Emerald Advisers, LLC |
| +1,94% | Wellington Management Company LLP |
| +1,72% | Geode Capital Management, LLC |
| +1,54% | Rosalind Advisors, Inc. |
| +1,42% | Sofinnova Ventures |
| +1,42% | State Street Corp |
| +1,26% | Emerald Mutual Fund Advisers Trust |
| +0,76% | Sphera Funds Management Ltd. |
| +0,65% | SUPERSTRING CAPITAL MANAGEMENT LP |
| +6,51% | Weitere |
| +11,72% | Streubesitz |
Zahlen für Q1/24
- Pivotal Phase 3 IMPALA-2 Trial Remains On-track, Top Line Results Expected by End of 2Q 2024
- the Company Continues to Believe it is Sufficiently Capitalized into 2026
https://savarapharma.com/investors/press-releases/release/?id=14706
